Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer

doi:10.4240/wjgs.v18.i2.112924

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 2

This Article

(46)

(45)

(0)

(686)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Surg. Feb 27, 2026; 18(2): 112924
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.112924

Full Size Figure Download Figure

Figure 3 Overall survival curves for patients with stage IIB-IIIC colorectal cancer by an inflammation-based prognostic marker at the preoperative and adjuvant chemotherapy time points (n = 445). Patients were stratified into two groups by C-reactive protein/albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). A: Preoperative CAR; B: Adjuvant chemotherapy CAR; C: Preoperative NLR; D: Adjuvant chemotherapy NLR; E: Preoperative PLR; F: Adjuvant chemotherapy PLR; G: Preoperative SII; H: Adjuvant chemotherapy SII. CAR: C-reactive protein/albumin ratio; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune-inflammation index.

Citation: Kong FF, Geng X, Liu RM, Zhang WT, Quan B, Zhong Y, Zhu YL. Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer. World J Gastrointest Surg 2026; 18(2): 112924
URL: https://www.wjgnet.com/1948-9366/full/v18/i2/112924.htm
DOI: https://dx.doi.org/10.4240/wjgs.v18.i2.112924

Kong FF, Geng X, Liu RM, Zhang WT, Quan B, Zhong Y, Zhu YL. Post-chemotherapy C-reactive protein/albumin ratio predicts prognosis in stage II-III colorectal cancer. World J Gastrointest Surg 2026; 18(2): 112924 [PMID: 41809326 DOI: 10.4240/wjgs.v18.i2.112924]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.